Novartis Medical’s Post

At TREAT-NMD, our commitment to advancing the diagnosis, treatment, and care for those affected by neuromuscular diseases is unwavering. We are thrilled to unveil our 2022 – 2023 impact report, showcasing the strides we've made in pursuit of this critical mission through: ✅ Informing the Community: Providing vital updates on research, trials, and best practice. ✅ Connecting Stakeholders: Connecting leaders, patient organisations, and industry partners to drive innovation. ✅ Advancing Therapeutics: Accelerating ground-breaking treatments and de-risking trials. This progress reflects our team's dedication and global collaboration. Explore our Impact Report > https://lnkd.in/erTbTSdp to learn more about our journey. Together, we're transforming lives. #TREATNMD #NeuromuscularDiseases #ImpactReport #TransformingLives

Shaping the future of Healthcare in Austria – by ensuring access to innovative treatment options. Last week, the results of a study were presented on patients´ access to innovative medicines in Austria.   The associated panel discussion held within the framework of European Forum Alpbach was based on a study conducted by Economica Institut für Wirtschaftsforschung and supported by Bristol Myers Squibb, examining access to innovative medications in Austria. While the key findings reveal satisfactory access in hospitals and for cancer treatments, significant challenges persist in the outpatient sector – particularly concerning practical and administrative hurdles.   A special thanks to Martin Gleitsmann CSE, N. Kamaleyan-Schmied, Ronald Pichler, Fiona Fiedler and Joseph Smolle for their participation in the expert discussion on this important topic!   Our goal is to ensure swift access to innovative treatments for all patients in Austria. We firmly believe that innovation has the power to change lives and enhance domestic innovation capabilities. Let's drive innovation forward, together!   #BMSAustria #EFA #EuropeanForumAlpbach

🔎 𝗛𝗮𝘃𝗲 𝘆𝗼𝘂 𝗵𝗲𝗮𝗿𝗱 𝗼𝗳 𝗚𝗹𝘆𝗰𝗮𝗻𝗧𝗿𝗶𝗴𝗴𝗲𝗿? 🔬 The GlycanTrigger EU Project, project also funded by the European Union's Horizon Europe program, focuses on the study of the crucial role of glycans within the immune modulation, in order to unlock new therapeutic approaches for chronic diseases and inflammatory conditions. By collaborating with leading researchers to translate cutting-edge science into real-world applications, GlycanTrigger promises to pave the way for novel treatments that can significantly improve patient outcomes. Through SPI - Sociedade Portuguesa de Inovação, we are actively involved in this project bringing the Dissemination, Communication, and Exploitation strategies to increase the project's impact. 📡 Stay tuned at : www.glycantrigger.eu Linkedin: https://lnkd.in/dCkqF7zE X: https://lnkd.in/dv8BDeFn Instagram: https://lnkd.in/dBn6Sx6R #Immunotherapy #HorizonEuropeProjects #GlycanTrigger #Innovation #Healthcare

Proud to support the management of #myastheniagravis in Belgium! Myasthenia gravis cannot be cured, but with proper and patient-tailored disease management many people can live their normal lives again, with minimal to no symptoms. Clinical guidelines can strongly improve physicians in providing the best possible care for patients.    As #optimisinghealthcare is what #Hict'ers live for we are proud to announce the publication of #clinicalrecommendations for the management of myasthenia gravis in Belgium: ✔ based on the latest scientific evidence; ✔ aligned with the Belgium reimbursement criteria; ✔ keeping in mind newer and (near) future therapies; ✔ with a focus on the practical implementation to optimally support our Belgian neurologists.   The manuscript has been published in #ActaNeurologicaBelgica. Read it here! https://lnkd.in/eCxN88G8    We truly appreciated collaborating with the authors, experts from the seven Belgian neuromuscular reference centers PROF. DR DE BLEECKER JAN, Kristl Claeys, Stéphanie Delstanche, Bissay, Véronique, Vinciane Van Parijs, Gauthier Remiche, Alicia Alonso-Jiménez and want to thank Alexion Pharmaceuticals, Inc., argenx, Johnson & Johnson, UCB for their support. Want to know more on how Hict handles such projects? Read the reference case on our website: https://lnkd.in/eiPdS8Mk

🔬 LIVe2024 RECAP: The Lung In Vitro Event 🫁 ✨️ A resounding success!   The LIVe2024 congress, organized by Epithelix and ALTERTOX in Nice, France (June 20-21), brought together scientists, industry leaders and regulatory experts interested in advancing in vitro respiratory research.    ✨ Cutting-edge models, real-world impact!  The focus was on the latest developments in in vitro lung models, with applications from basic research to drug discovery, efficacy testing and toxicity assessment.    ✨ Collaboration for a healthier future!  LIVe2024 fostered lively discussions on how these innovative models can accelerate progress in lung disease treatment.     Let us know in the comments what you found most interesting about the #LIVe2024 Congress!     #LIVe2024 #Invitro #Lungresearch #NAMs #Congress 

‘93% of respondents want testing capacity investment so that test results and diagnosis is quicker. 91% want investment in diagnostics and new technology to be prioritised.’ And yet the healthcare systems around the world are behind with diagnostics. There is less focus from manufacturers on diagnostics because it is not as profitable as other areas of the industry and yet having the correct diagnosis is critical for treating patients.

The National institute for Clinical Excellence (NICE) in the #UK has indicated in its 2021-2026 Transformation Plan that the use of Real World Evidence as outlined in the framework document ( https://lnkd.in/eBwEKwV2 ) can improve our understanding of health and social care and the effects of interventions on patient outcomes. Contact DaSH Global on [email protected] to discover how we are harnessing the latest technology to drive change in the treatment of Lung Cancer and Mesothelioma. DaSH Global: Improving Outcomes. Transforming Lives. Bridging The Gap Between People, Health & Pharma #NICE #TransformationPlan #RWE #SocialCare #PatientOutcomes #Healthcare #NHS #LungCancer #Mesothelioma #Pharma #MarketAccess Vivienne Law Andrew Turner Lee Wemyss

It is important to consider all six R's to succeed in drug development," proclaimed Gunilla Osswald, CEO of BioArctic, at Nordic Life Science Days in Copenhagen. The Nordic regions are one of the world-leading regions when it comes to biomarker development and strong innovation. I am happy to see the breakthrough in Alzheimer's disease. The 6 R:s 1. Right target 2. Right patient population 3. Right dose and exposure 4. Right measurements 5. Right safety 6. Right partner

The fallacy of sepsis diagnosis is that a single test/biomarker can solve for the answer. Since sepsis is a complex syndrome and not a diagnosis in the traditional sense Novel and unconventional approaches are required for its early and accurate detection. Check out sepsis Immunoscore.

#ESHAL2024 #ESHCONFERENCES Dr. med. Nicola Gökbuget, head of the German Multicenter Study Group for Adult ALL (GMALL), discussed selection and sequencing of immunotherapies in 1st line management of adult #ALL: Inotuzumab and/or Blinatumomab. Data from international trials show that both substances have their eligibility depending on the patient and the goal you want to achieve. While Inotuzumab is a good substance for debulking, Blinatumomab does a really good job at eradicating MRD. The open question that needs to be addressed moving forward: are we able to replace chemotherapy in the future?  4th How to Diagnose & Treat ACUTE #LEUKEMIAS conference Chairs: Hervé Dombret, Gert Ossenkoppele, Christoph Röllig, Wendy Stock #leusm #ESHELEARNING